StemCell Technologies’ Contract Services Presents Educational Webinar on Erythropoietin (EPO) Signaling and Erythroid Development
“A guide to erythropoiesis: EPO signaling and erythroid development” will be presented by Dr. Jackie Damen on March 12, 2008 at 11:00 AM PST.
Discovery Could Help Reprogram Adult Cells To Embryonic Stem Cell-like State
In a paper released online by the journal Cell Stem Cell, researchers report that they have discovered how long adult cells need to be exposed to reprogramming factors before they convert to an embryonic-like state, and have “defined the sequence of events that occur during reprogramming.”
Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice
Novocell, Inc. has announced data demonstrating for the first time that human embryonic stem (hES) cells can be turned into pancreatic cells capable of producing insulin in mice
Advanced Cell Technology Demonstrates Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells
Advanced Cell Technology, Inc. has reported for the first time a robust and highly efficient process for the generation of high-purity hepatocytes.
Reprogramming Cells Taken from Disease Sufferers Could Lead to New Treatments
The discovery late last year of a way to generate stem cells from adult skin cells could allow scientists to study disease in unprecedented detail, from earliest inception to final biochemical demise. That’s because the stem cells could be used to develop cell lines derived from people with a given disease-neurons from Alzheimer’s patients, for example, or blood cells from people with sickle cell anemia.
Stem Cell Jabs Reverse Damage After Strokes, Doctors Claim
Hopes that a therapy may be on the horizon were boosted by experiments which showed human embryonic stem cells could be turned into a variety of brain cells, which helped animals recover from strokes without causing dangerous side effects.
New Acute Lung Injury Study Finds Benefits of Autologous Cell Transplantation Therapy
A study published in this month’s Anesthesiology highlights the potential of cell-based therapies for the treatment of acute lung injury and acute respiratory distress syndrome.
Gene Therapy ‘Trains’ Immune System To Destroy Brain Cancer Cells And Reverses Behavioral Deficits
A new gene therapy approach that attracts and “trains” immune system cells to destroy deadly brain cancer cells also provides long-term immunity, produces no significant adverse effects and – in the process of destroying the tumor – promotes the return of normal brain function and behavioral skills.
Tumor-killing Virus Selectively Targets Diseased Brain Cells
New findings show that a specialized virus with the ability to reproduce its tumor-killing genes can selectively target tumors in the brains of mice and eliminate them.
Emory Begins Testing New Alzheimer’s Disease Vaccine
Doctors at Emory University will begin testing a vaccine designed to slow the accumulation of amyloid plaques in the brains of patients with Alzheimer’s disease.
Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
Northwest Biotherapeutics, Inc. has announced the most recent long-term follow-up data, as of year-end 2007, on disease progression and overall survival in patients taking part in its Phase I and Phase I/II clinical trials for newly diagnosed patients with Glioblastoma multiforme, the most aggressive form of brain cancer
Cell-Enhanced Breast Reconstruction Study Shows Sustained Improvement at 12-Months
Cytori Therapeutics was informed that positive longer-term follow-up data were presented today from an independent, investigator-sponsored breast reconstruction study in Japan. As part of the study, adipose tissue-derived stem and regenerative cells, processed with Cytori’s Celution(TM) 600 System, were used to reconstruct breast tissue following partial mastectomy.
Introgen’s p53 Immunotherapy INGN 225 Begins Randomized, Controlled Clinical Trial in Patients with Small Cell Lung Cancer
The controlled, randomized phase 2 trial, which will be led by Principal Investigator Dr. Alberto Chiappori, in the Department of Interdisciplinary Oncology at Moffitt, will evaluate the efficacy and safety of INGN 225 in as many as 80 patients with extensive stage SCLC at multiple centers.
$150,000 for a Pet Dog, Just Like Your Last One
A Californian dog-lover has agreed to pay $150,000 to have her dead pit bull recreated in the world’s first commercial pet cloning project.
ABSTRACTS, REVIEWS AND SPECIAL REPORTS
Prospects for Stem Cell-Based Therapy
Resident pools of somatic stem cells in many organs are responsible for tissue maintenance and repair. The goal of regenerative medicine is to exploit these cells either by transplanting them from an exogenous source or by activating endogenous stem cells pharmacologically. For diseases caused by mutations in a single gene, the therapeutic goal is tissue replacement using stem cells engineered to correct the genetic defect. However, a number of technical hurdles must be overcome before therapies based on pluripotent human stem cells can enter the clinic.
Stem Cell Biotech: Seeking a Piece of the Action
Venture capital groups and big pharma have largely held back from investing in biotech companies focused on regenerative medicine. Will it take a clinical bull’s eye to bring venture capitalists and big pharma into the cell therapy arena?
Cell Therapy Business Development Leader
Portland, OR (Invitrogen)